Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present-Reference-Cited by-同舟云学术

Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present

Published:2022-03-10 Issue:13 Volume:28 Page:2738-2743
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Franses Joseph W.¹^ORCID,Zhu Andrew X.¹²^ORCID

Affiliation:

1. 1Massachusetts General Hospital, Department of Hematology-Oncology, Harvard Medical School, Boston, Massachusetts.

2. 2Jiahui International Cancer Center, Shanghai, China.

Abstract

Abstract Hepatocellular carcinoma (HCC) remains a lethal malignancy and is an increasingly common cause of cancer death worldwide. Curative-intent surgical resection remains the standard of care for eligible patients, yet outcomes remain poor for many patients, with most patients experiencing recurrence in the 5 years after resection. There is currently significant interest in using locoregional and systemic therapies—in both the neoadjuvant and adjuvant settings—to increase the chance of cure. This review article appraises the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-0025/3055235/ccr-22-0025.pdf

Reference72 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

3. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function;Li;Hepatobiliary Pancreat Dis Int,2015

4. A global risk score (GRS) to simultaneously predict early and late tumor recurrence risk after resection of hepatocellular carcinoma;Dekervel;Transl Oncol,2016

5. Liver fibrosis and repair: immune regulation of wound healing in a solid organ;Pellicoro;Nat Rev Immunol,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Therapies in Hepatocellular Carcinoma: Insights from a Disulfidptosis-Related Signature;2024-01-24

2. Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib;Digestive and Liver Disease;2024-01

3. ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma;iScience;2023-12

4. Prognosis of repeat hepatectomy for liver transplantable hepatocellular carcinoma recurrence after hepatectomy: a Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO);Langenbeck's Archives of Surgery;2023-08-16

5. Prognosis of repeat hepatectomy for liver transplantable hepatocellular carcinoma recurrence after hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO);2023-04-13